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The present clinical staging of melanoma stratiﬁes patients into heterogeneous groups, resulting in the application of aggressive
therapies to large populations, diluting impact and increasing toxicity. To move to a new era of therapeutic decisions based on
highly speciﬁc tumor proﬁling, the discovery and validation of new prognostic and predictive biomarkers in melanoma is critical.
Genomic proﬁling, which is showing promise in other solid tumors, requires fresh tissue from a large number of primary tumors,
and thus faces a unique challenge in melanoma. For this and other reasons, proteomics appears to be an ideal choice for the
discovery of new melanoma biomarkers. Several approaches to proteomics have been utilized in the search for clinically relevant
biomarkers, but to date the results have been relatively limited. This article will review the present work using both tissue and
serum proteomics in the search for melanoma biomarkers, highlighting both the relative advantages and disadvantages of each
approach. In addition, we review several of the major obstacles that need to be overcome in order to advance the ﬁeld.
1.Introduction
The ﬁeld of oncology is rapidly attempting to move to
a new era of personalized therapy, where individualized
therapeutic decisions are based on highly speciﬁc tumor
proﬁling. For this to become a reality, the discovery and
validation of new prognostic and predictive biomarkers are
necessary. This goal seems increasingly realistic thanks to
high-throughput screening methods, particularly genomic
proﬁling. The large-scale analysis of gene expression has
improved our knowledge of tumorigenesis, invasion, and
metastasis.Morerecently,geneexpressionassayshave helped
guide therapeutic decisions, such as the use of multigene
assays for decisions regarding systemic therapy in breast
cancer [1, 2]. However, despite continued success in the
preclinical setting, clinical translation has been slow and
several tumor types present unique challenges to the use of
genomic proﬁling.
One example is melanoma. The present staging system
for melanoma, using Breslow thickness, ulceration, mitotic
rate, and the presence of regional and distant metastases,
stratiﬁes patients into heterogeneous groups, with wide
variability in outcome or response to therapy. Clinically, this
results in applying more aggressive surgical and adjuvant
therapies to large populations, diluting the impact of therapy
while exposing more patients to toxicity. For those treating
melanoma, better prognostic and predictive markers in
melanoma are sorely needed, but to date have been elusive.
The high-throughput analysis of genomic data requires fresh
tissue from a large number of primary tumors. This presents
a unique challenge in melanoma where the primary is often
onlyafewmillimetersinsize,withnoresidualtissueafterthe
diagnosishasbeenmade.Forthisreason,proteomicsappears
to be an ideal choice for the discovery of new prognostic and
predictive biomarkers in melanoma.
There are other potential advantages to proteomics over
genomics. Genes are transcribed into mRNA, but because
cells can use alternative splicing, there is no one-to-one
relationship between the genome and the transcript. The
transcripts are further translated into proteins, which often
undergo posttranslational modiﬁcations (PTMs), or can be
aberrantincancercells.Therefore,onegenecanresultinsev-
eral diﬀerent protein isoforms. Protein structure can also be
inﬂuenced by environmental factors, including interaction2 International Journal of Proteomics
with other proteins, degradation, or compartmentalization
of proteins within protein complexes. As the structure and
availability of the ﬁnal versions of the proteins ultimately
determine the behavior of the cell, high-throughput screen-
ing methods for changes in protein expression may be better
suited to identify biomarkers with prognostic or predictive
value.
2. BiomarkersinMelanoma
The clinical potential for melanoma biomarkers covers
the spectrum of disease. Protein changes associated with
the transition from melanocyte to atypia or dysplasia and
ultimately to melanoma could be used to aid in diagnosis
or to screen high-risk patients. Proteins associated with
pathophysiology and malignant properties could be used
to further classify melanoma, stratifying patients by risk of
recurrence in order to better select surgical and adjuvant
treatments.Likewise,proteinexpression(baselineorchanges
in expression) may predict response to speciﬁc therapies, so
that selection of systemic therapies can be tailored to the
individual patient. The detection of low levels of melanoma-
associated proteins in the serum may also lead to early
recognition of recurrent disease or monitoring the response
to therapy for metastatic disease.
Despite the signiﬁcant potential for tissue-based or
serological biomarkers to help diagnose early stage disease,
tailor therapy, or detect recurrence, very few biomarkers are
in clinical use. Several tissue markers are used to help distin-
guishmelanomafromothertypesofcancers,includingS100,
MART-1, and gp100/HMB45. To date, however, there are no
tissue-based biomarkers that are utilized clinically for prog-
nostic classiﬁcation. This is despite the identiﬁcation of mul-
tiplebiomarkers,throughgenomicorimmunohistochemical
analysis, whose abnormal expression has been linked to poor
outcome.Theseincludetumorsuppressors/oncogenes/signal
transducers (p16, PTEN, EGFR, c-KIT, c-myc, bcl-6, HER3),
cell-cycle associated proteins (Ki67, Cyclins A, B, D, E,
p21, Geminin, PCNA), regulators of apoptosis (bcl-2, bax,
Bak, ING3, ING4), proteins involved with cell adhesion
and motility (P, E and N-cadherin, β-catenin, β1a n dβ3
integrins, matrix metalloproteinases (MMPs)), and others
(Hsp90, RGS1, NCOA3, MCM4, MCM6) [3, 4].
There have also been several serologic markers that have
been associated with poor prognosis. These include diﬀer-
entiation antigens (S100β, MIA, tyrosinase), proangiogenic
factors (vascular endothelial growth factor (VEGF), basic
ﬁbroblast growth factor (BFGF), IL-8), cell adhesion and
motility molecules (soluble intracellular adhesion molecule
1 (sICAM-1), soluble vascular cell adhesion molecule 1
(sVCAM), MMP-1, MMP-9), cytokines (IL-6, IL-10, soluble
IL-2 receptor (sIL-2R)), and others (TA90 immune complex,
YKL-40) [3–5]. However, only two of these are utilized
clinically.
The strongest prognostic serum biomarker is lactate
dehydrogenase (LDH), which correlates with tumor load in
advanceddiseaseandisthestrongestindependentprognostic
factor in stage IV melanoma [6]. It is the only biomarker
included in the AJCC staging system [7] and is often used
to stratify patients for randomized trials in stage IV disease.
There is limited beneﬁt, however, to the measurement of
LDH among patients with earlier stage disease, particularly
in the followup of patients who appear tumor-free after
surgical resection.
The S100 protein consists of two subunits, alpha and
beta. The beta subunit is expressed in cells of melanocytic
lineageandisoftenusedasanimmunohistochemicalmarker
for histological diagnosis of melanoma. Serum S100β has
also been studied as a prognostic biomarker. Several studies
have demonstrated an association between serum S100β
levels and outcome, independent of stage. S100β serum
concentrations can be a useful marker for monitoring
therapy response in patients with advanced disease. While
some European guidelines recommend routine S100β mea-
surements as part of the surveillance of melanoma patients,
[8, 9], there is limited evidence that this impacts outcome
[10, 11].
3. TissueProteomics inMelanoma
Proteomic approaches can be divided into two categories:
those that characterize the entire protein complement of the
cells or tissue of interest and those that examine only those
proteins found in speciﬁc specimens (primarily blood, but
this could also include other ﬂuids such as saliva or urine).
Several groups have utilized functional proteomics to iden-
tify alterations in protein expression and posttranslational
modiﬁcations to identify markers of melanoma progression
aswellaspredictivemarkers,suchasidentifyingproteinsthat
may be associated with response to therapy (Table 1). While
this approach has been utilized across a spectrum of primary
tumors, it is more diﬃcult in melanoma secondary to the
limited accessibility of primary melanoma tissues. Therefore
most of this work has been carried out in melanoma cell
lines.
Two-dimensional electrophoresis (2DE) has been the
mainstay tool for separating proteins for many years.
Proteins in a 2-dimensional gel are separated in the ﬁrst
dimension based on isoelectric points and then in a sec-
ond dimension based on molecular masses. Diﬀerences
between the samples can be compared and relative quantities
determined by quantifying the ratios of spot intensities in
the 2D gels. Matrix-assisted desorption/ionization time of
ﬂight mass spectrometry (MALDI-TOF MS) can then be
used to analyze small amounts of protein isolated from the
gel. The mass information obtained can then be used for
protein identiﬁcation using an appropriate protein sequence
database and search program.
Bernard et al. [12] used 2DE and mass spectrometry
to identify proteins that diﬀerentiated melanocytes from
melanoma cell lines and therefore may be important in the
early progression to melanoma. Two proteins, nuclophos-
min/B23 and hepatoma-derived growth factor (HDGF),
were strongly upregulated in melanoma, while cathepsin
D was downregulated in melanoma cell lines. Carta et al.
[13] also used 2DE and mass spectrometry to examine theInternational Journal of Proteomics 3
Table 1: Proteomics for biomarker discovery in melanoma.
Author Year Specimens Comparison Methodology Proteins of interest
Bernard et al. [12] 2003 Cell lines
Melanocyte versus
melanoma (primary and
metastatic)
2DE and mass
spectrometry
Nucleophosmin/B23,
HDGF, CTSD
Sinha et al. [14] 2003 Cell lines
Responsive to
chemotherapy versus
nonresponsive
2DE and
MALDI-TOF Multiple (25)
Wilson et al. [28] 2004 Serum
Stage I or II melanoma
patients, recurrence versus
none
SELDI-TOF n/a (expression proﬁles)
Carta et al. [13] 2005 Cell lines Primary versus metastatic
melanoma
2DE and mass
spectrometry
HSP27, HSP60, HSPA8,
PRDX2
Mian et al. [29, 30] 2005 Serum Stage I melanoma versus
Stage IV melanoma SELDI-TOF n/a (expression proﬁles),
further work identiﬁed
SAA
Mian et al. [29, 30] 2005 Serum
Stage III melanoma
patients, recurrence versus
none
SELDI-TOF
Takikawa et al. [24] 2009 Serum Volunteers versus
melanoma patients
Nano LC and
MALDI-TOF PPBP
Caron et al. [27] 2009 Serum Volunteers versus
melanoma patients SELDI-TOF n/a (expression proﬁles)
Greco et al. [31] 2009 Serum Patients undergoing biopsy,
melanoma versus not
2DE and
MALDI-TOF TTR, AGT, DBP
Paulitschke et al.
[46] 2009
Secreted proteins
f r o ma n dc e l ll i n e s
and skin samples
Normal skin versus
Melanoma
Nano LC and
mass
spectrometry
GPX5, periostin,
stanniocalcini-1
Suzuki et al. [36] 2010 Serum Volunteers versus
melanoma patients
Autoantibody
detection
EEF2, ENO1, ALDOA,
GAPDH, HNRNP-A2B1
Hood et al. [47] 2010 Cell lines Melanoma versus normal
skin
Nano LC and
mass
spectrometry
Tenascin-C, ﬁbronectin,
ACN4, TSP-1
Liu et al. [37] 2010 Serum Node negative versus node
positive melanoma patients
Autoantibody
detection
GRP94, ASAH1, CTSD,
LDHB
Hardesty et al. [16] 2011 Surgically resected
lymph nodes
Recurrence versus no
recurrence MALDI-IMS Cytochrome C calmodulin
HDGF: hepatoma-derived growth factor, CTSD: cathespin D, PPBP: prop-platelet basic protein precursor, SAA: serum amyloid A, TTR: transthyretin, AGT:
angiotensinogen, DBP: vitamin D binding protein, EEF2: eukaryotic elongation factor 2, ENO1: enolase 1, ALDOA: aldolase A, GAPDH: glyceraldehyde-3-
phosphatedehydrogenase,HNRNP-A2B1:heterogeneousnuclearribonucleoproteinA2B1,ACN4:alpha-actinin-4,TSP-1:thrombospondin-1,GRP94:94kD
glucose-regulated protein, ASAH1: acid ceramidase, LDHB: lactate dehydrogenase B.
proteomes of cultured melanocytes and melanoma cell lines
from primary and metastatic lesions. They identiﬁed several
candidate proteins, many of which were stress proteins. They
then used RT-PCR to evaluate mRNA expression of these
proteins and found that overexpression of HSP27, HSP60,
and HSPA8 and downregulation of PRDX2 were observed
more commonly in metastatic melanoma versus primary
melanoma.
As opposed to identifying proteins associated with
melanoma development and progression, Sinha et al. [14]
compared melanoma cell lines with varying degrees of
resistance to commonly used anticancer drugs to iden-
tify proteins that may be responsible for resistance to
therapy. Starting with a single melanoma cell line, they
created a panel of sublines that exhibited diﬀerent levels
of drug sensitivity [15]. Using 2DE and matrix-assisted
laser desorption/ionization-time of ﬂight (MALDI-TOF)
mass spectrometry for protein identiﬁcation, they identiﬁed
a variety of proteins that were diﬀerentially expressed in
chemoresistant melanoma cell lines, many of which were
chaperones, including heat-shock proteins (HSPs).
These studies utilized electrophoresis to physically sep-
arate the proteins, requiring the use of melanoma cell lines.
Hardestyetal.[16]usedMALDI-imagingmassspectrometry
(MALDI-IMS) analysis, which acquires information from
intact proteins directly from thin sections of the tissue
[17]. This allows for the analysis of speciﬁc cellular regions
and precludes the need to generate a cell line from which4 International Journal of Proteomics
the proteins are isolated. Using lymph nodes involved
with metastatic melanoma from 69 stage III patients, they
identiﬁed two proteins that were associated with recurrence,
cytochrome C and calmodulin, with a better prognosis as the
intensity of both proteins increase.
While this approach is applicable to patients with larger
metastatic deposits, such as clinically involved lymph nodes,
it is not useful for discovery of primary tumor biomarkers.
For approximately 90% of melanoma patients, the entire
primary tumor is excised during the initial biopsy, so
proteomic investigations requiring fresh or frozen primary
tumor tissue are not applicable. Many academic centers have
collections of formalin-ﬁxed paraﬃn-embedded (FFPE)
melanoma specimens, with accompanying clinicopathologic
and outcome data. If these specimens could be used to
scrutinizetheproteome,theuseofproteomicsformelanoma
biomarker discovery would take a giant leap forward. Unfor-
tunately, FFPE tissues are typically refractory to proteomic
investigationsusingtoday’smethodologies,largelyduetothe
high level of covalently linked proteins arising from formalin
ﬁxation [18]. Shotgun proteomics involves direct digestion
of protein mixtures to complex peptide mixtures which are
then separated and analyzed. These approaches can be used
to extract proteins or peptides from ﬁxed tissues for analysis.
Several proteomics studies using FFPE tissue have been
reported [19–22]. A newer approach, a modiﬁed shotgun
proteomic strategy, termed direct tissue proteomics (DTP),
can extract and identify peptides and proteins directly from
t i s s u e su s i n gm i c r o - r e v e r s e - p h a s e( μRP) LC-MS/MS and has
been proposed for use in melanoma [18, 23]. While there
are still several obstacles to overcome, DTP with eﬃcient
extraction of proteins from FFPE tissue could open up a
new avenue of retrospective proteomics-based biomarker
investigation in melanoma.
4. Serum Proteomics
As discussed, examining the entire proteome of the cell
of interest requires either the generation of a cell line or
adequate harvestable tissue, which inherently limits and
biases the study population. This presents several obstacles
to both validating the ﬁndings and ultimately using them
clinically. Blood carries not only plasma-speciﬁc proteins but
also multiple proteins derived from other tissues, including
tumors. Many proteins are secreted, shed, or lost into the
circulation, either directly by tumor cells or indirectly after
destruction of the tumor cells. The development, validation,
and use of serum tests hold several potential advantages
over tests that require primary tumor tissue, particularly for
melanoma.Asanexample,Takikawaetal.[24]comparedthe
serum proteome between healthy volunteers and melanoma
patients using NanoLC and MALDI-TOF-MS, and identiﬁed
9 proteins detectable in plasma from the melanoma patients
but not healthy plasma. Ultimately they identiﬁed pro-
platelet basic protein precursor (PPBP) as a protein whose
level corresponded with outcome and may serve as a sero-
logical prognostic biomarker.
Several investigators have utilized surface-enhanced laser
desorption/ionization (SELDI) and protein chip technology
to ﬁnd serum protein patterns that may be associated
with the presence or the stage of melanoma. While gene
chips have allowed for the detection of thousands of genes
from very small samples, the creation of protein chips has
faced several obstacles. Compared to DNA, proteins are
not as robust and tend to denature. Proteins are more
diﬃcult to attach to chip surfaces, and while PCR can be
used to amplify DNA, there is no method of amplifying
minuteamountsofprotein.TheProteinChipBiologySystem
uses SELDI-TOF MS to retain proteins on a solid-phase
chromatographic surface that are subsequently ionized and
detected by TOF MS [25, 26]. The surface of the ProteinChip
is designed to select proteins from extracts due to either
chemical (anionic, cationic, hydrophobic, hydrophilic) or
biochemical (antibody, receptor, DNA, enzyme) properties.
This is a more user-friendly approach to proteomics; SELDI
has several advantages over other technologies for high-
throughput screening as it is rapid, of relatively low cost,
andreproducible.Itrequiressmalleramountsofsamplethan
2DEasproteinproﬁlescanbemadefromfewercells.Itisalso
readily adaptable to a diagnostic format.
This technology can be used to detect protein expression
patterns and then compare these patterns between diﬀerent
population sets. These patterns could be used as a clinical
diagnostic test. Caron et al. [27] used this technology to try
and discriminate between serum samples from melanoma
patients and healthy volunteers and demonstrated a good
diagnostic accuracy of 98.1% (sensitivity 96.7%, speciﬁcity
100%). Wilson et al. [28] examined the serum from patients
with AJCC stage I or II melanoma who recurred (n =
25) or did not (n = 24) using SELDI ProteinChip mass
spectrometry (MS) and identiﬁed three protein expression
pattern diﬀerences that could discriminate between the two.
Mian et al. demonstrated the potential of this technology
with artiﬁcial neural networks (ANNs) to discriminate
between serum samples from 101 stage I melanoma patients
and 104 stage IV melanoma patients, as well as from 28 stage
III patients who recurred from 27 stage III patients who did
not [29]. Further research, focusing on the highest peak,
ultimately identiﬁed serum amyloid A (SAA) as a potential
prognostic biomarker in melanoma [30].
There are some drawbacks to serum-based proteomics.
The expression and release of proteins into the serum can be
variable. As an example of this, Greco et al. [31] obtained
serum from 50 patients undergoing biopsy for suspected
melanoma.Using2DEandMALDI-TOF-MS,theyidentiﬁed
increasesoftransthyretin(TTR)andangiotensinogen(AGT)
and decreased expression of vitamin D binding protein
(DBP). The investigators also examined serum samples after
surgical removal of the melanoma and found that these
were no longer elevated 1 month after surgery. This is an
important consideration in melanoma patients, particularly
if one is seeking to develop a prognostic serum test. This
test would most likely be ordered after the diagnosis of
melanoma and therefore might be greatly impacted by
whether or not the entire tumor was removed with the
diagnostic biopsy.
Another drawback to serum proteomics is that most
(97%) of the proteins found in plasma belong to one of 7International Journal of Proteomics 5
major groups of high-abundance plasma proteins: albumin,
immunoglobulins, ﬁbrinogen, alpha-1 antitrypsin, alpha-
2 macroglobulin, transferring, and lipoproteins. As these
are primarily proinﬂammatory proteins, they are unlikely
to represent prognostic or predictive biomarkers. SELDI
pattern recognition studies do not depend on detecting low-
abundance proteins, but depend instead on ﬂuctuations of
protein expression patterns. Therefore this technology, as
well as others, is limited in speciﬁcally identifying low-
abundance proteins that may be useful biomarkers.
5.Antibody-BasedProteomics
An alternate approach to examining the proteome directly
is to screen for antibodies in the serum of patients with
melanoma.Aswithserum-basedproteomics,primarytumor
tissue from each patient is not required, a signiﬁcant
advantage in melanoma patients. Another advantage is that
antibodies are more sensitive and stable than proteins,
which is clinically important in creating clinically useful
diagnostic or prognostic tests. Antibody-based proteomics
is particularly well suited to melanoma as the presence of
an immune response to melanoma-associated antigens has
been well documented [32–35]. Monitoring the presence or
absence of antibodies in the serum that recognize speciﬁc
tumor antigens can provide insights into the propensity
of melanoma to metastasize, serving as biomarkers of
melanoma biology and perhaps identifying ideal targets for
therapeutic intervention.
There are several high-throughput methods for the
discovery of autoantibodies including serological screen-
ing of cDNA expression libraries (SEREX), phage display
libraries and proteomics-based techniques. Serological pro-
tein analysis (SERPA) uses 2DE to separate proteins from
tumor tissues or cell lines which are then transferred onto
membranes by electroblotting and subsequently probed
with sera from diﬀerent populations of interest. Suzuki
et al. [36] used this approach to identify 5 proteins that
diﬀerentiated serum samples from melanoma patients and
healthy volunteers (eukaryotic elongation factor 2 (EEF2),
enolase 1 (ENO1), aldolase A (ALDOA), glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), and heterogeneous
nuclear ribonucleoprotein (HNRNP-A2B1).
Another proteomics-based approach to detecting serum
autoantibodies is the use of protein microarrays. Pro-
tein microarrays spot proteins (puriﬁed, recombinant, or
extracted from tumor cell lysates) onto microarrays which
can be two-dimensional (glass slides, nitrocellulose mem-
branes and microtitre plates) or three-dimensional (beads,
nanoparticles). These are then incubated with sera from
diﬀerent populations. Advantages include the fact that
less sample and reagents are needed, and autoantibodies
to proteins with posttranslational modiﬁcations, such as
glycosylated proteins, can be detected. There are, how-
ever, challenges to identifying the speciﬁc immune-reactive
proteins in the respective protein fractions. Rather than
screening the entire proteome, Liu et al. [37]f o c u s e do n
the subproteome of glycoproteins. Dual-lectin (ConA and
WGA) aﬃnity chromatography was applied to extract both
glycoproteins from the lysate of a cell line generated from an
intra-abdominal melanoma metastasis. Liquid-based reverse
phase separation and natural protein microarray were then
applied to separate the enriched proteins and spot the
separated fractions on nitrocellulose slides. These were used
to probe the sera from patients with newly diagnosed
melanoma for antibodies that correlated with the presence
of regional metastases. After validation, antibodies to 4
proteinsincluding94kDglucose-regulatedprotein(GRP94),
acid ceramidase (ASAH1), cathepsin D (CTSD), and lactate
dehydrogenase B (LDHB) were identiﬁed that diﬀerentiated
node-negative from node-positive patients.
6. ClinicalTranslationandObstacles
Although the clinical potential of both tissue and serum-
based proteomics in melanoma biomarker discovery seem
strong, progress has been relatively limited to date. The
reasons for this are multifactorial, both related to the
inherent obstacles speciﬁc to melanoma and problems with
study design. For the ﬁeld to advance, several issues need to
be tackled.
A key obstacle to biomarker discovery is reproducibility.
This has been a signiﬁcant problem with proteomics. As an
example, in a meta-analysis of prostate cancer proteomic
data obtained with SELDI-TOF, published results seem to
diﬀer greatly between diﬀerent groups, and even from within
the same groups [38, 39]. As evidenced in Table 1, there
is little overlap between the proteins identiﬁed by diﬀer-
ent groups using diﬀerent techniques. There are multiple
approaches to proteomics, each with signiﬁcant advantages
and disadvantages depending on what the question is. Com-
pared with serum proteomics, tissue proteomics has a higher
likelihood of identifying marker candidates based on the
higher concentration of protein within the tissue than after
dilution in peripheral blood. For melanoma, the use of cell
lines is most feasible however results are immediately biased
by(1) selecting patients withharvestable tumor,(2) selecting
melanomas that grow well in vitro, and (3) by changes in
protein expression induced by in vitro culturing. Variations
incellculturetechniquecouldyielddiﬀerentresultsfromthe
same cell line. Using tissue obtained directly from patients
avoids some of these issues, but limits the patient population
and hence the questions that can be asked. In addition, the
results obtained can be greatly impacted by stroma, necrotic
tissue, serum proteins, and blood cells within the specimen.
Pure cancer cell populations can be created using ﬁne needle
aspiration, calciumstarvation, immunomagnetic separation,
or laser capture microdissection (LCM), [40–43] but this is
extremelydiﬃculttodowhenthereisalimitedsupplyofpri-
mary tumor tissue. Until newer technologies for examining
FFPE tissues are more fully developed, this approach will be
limited to select patient populations. Serum proteomics may
identify fewer candidate proteins, but given the drawbacks of
tissue proteomics in melanoma, this approach may be more
translatable to clinical use. Examining the serum proteome is
impossible without reducing the complexity of the protein
mixture by removing highly abundant serum proteins, for6 International Journal of Proteomics
which there are also several methods. When the blood is
drawn, how it is stored, and whether serum or plasma is
usedcanpotentiallyimpacttheresults.Thereforeonecansee
that before any analysis is even performed, variations in the
methods used to prepare the samples (cell culturing, tissue
procurement, extraction of highly abundant serum proteins)
can signiﬁcantly impact the results. The methods used to do
this must be highly reproducible, as even small variations in
buﬀers or agents can alter the results. It becomes easy to see
how radically diﬀerent results can be reached even when the
same experimental technique is utilized [44].
Quite often, initial experiments are designed based on
the available samples and technologies, without as much
forethought into the clinical question that the ﬁndings hope
to address. In melanoma, for example, tissue proteomics are
often carried out on samples from resected lymph nodes
and metastatic deposits, as there is ample tissue available.
Clinically, however, this is a population with a very poor
prognosis, and outside of very speciﬁc questions, it is less
likely that biomarkers identiﬁed from these highly dediﬀer-
entiated samples would impact clinical decision making or
serveasusefulbiomarkersinpatientswithearlystagedisease.
It is imperative that translational oncology be hypothesis
driven, whereby even discovery studies are designed with
a speciﬁc clinical question in mind. Even something as
simple as when blood samples are obtained, if they do not
reﬂect when they would be drawn in the clinical setting,
could negatively impact the results. Close collaboration
between clinical experts in melanoma and basic scientists is
imperative to results that have a high likelihood of clinical
impact.
Patient selection is also critical to results that are
both reproducible and clinically relevant. In oncology, it
is quite common to discover a biomarker among a highly
heterogenous group of patients that on univariate analysis
is signiﬁcantly associated with outcome, but in reality
correlates so strongly with known staging factors (tumor
size, grade) that on multivariate analysis it provides no
independent prognostic information. While these may be of
scientiﬁc interest in unraveling the genes/proteins associated
with dediﬀerentiation and metastases, they are of limited
clinical beneﬁt in stratifying patients beyond our current
staging systems. It is therefore imperative that samples be
obtained from as homogenous a population as is feasible and
in adequate numbers so that newly discovered biomarkers
are analyzed in the context of the known prognostic and
predictive factors used in clinical decision making. Often
smaller and more heterogeneous sample sets are chosen for
practicalreasons,whichunfortunatelycontributetothelarge
number of reported biomarkers that are never validated or
demonstrate clinical utility.
Equally important is the appropriate selection of con-
trols. For prognostic markers meant to diﬀerentiate between
melanoma patients with diﬀerent outcomes, it is imperative
that the “good” cohort have adequate followup to be sure
that this is truly a group at low likelihood of recurrence.
Frequently these controls only have a median followup of 2-
3 years. With longer followup, several of the “good” players
may recur, and with small sample sets the conversion of only
1or2patientsfrom“good”to“bad”candramaticallychange
the results. Likewise, the search for biomarkers associated
with melanoma development, with potential use as a screen-
ing tool, often compares melanoma patients (of varying
stages) to healthy volunteers. Neither of these populations
is appropriate—the melanoma group should only include
patients with early stage, recently diagnosed disease, and the
control group should not be healthy volunteers but rather
high-risk individuals with similar characteristics regarding
age and sun exposure.
While the ﬁeld of proteomics and other “-omics” ﬁelds
are replete with articles describing discovery, there are
dramatically fewer articles validating previously published
results. Several reports include internal validations, using a
fraction of their samples for discovery and then validating
the results in the complete set. However, the bioinformatics
tools used in discovery sets often seek to overﬁt the data,
erring on the side of not missing a potential biomarker, but
resulting in sensitivities and speciﬁcities that may not be
reproducible. Even if an institution is able to validate their
own ﬁndings, given the impact that sample preparation and
patient selection can have, validation from other institutions
is absolutely critical. Beyond interlaboratory variations,
many biomarkers demonstrate varying expression based
on patient characteristics (age, race and ethnicity, genetic
lineage, environmental exposures). Therefore, biomarkers
discovered and validated on a population in one geographic
area may not be validated on another, even though the
techniquesarethesameandthepopulationsappearmatched
by known prognostic factors (Breslow thickness, nodal
status, etc.). Unfortunately, there is limited enthusiasm for
one institution to attempt and validate a published result.
Validation requires larger numbers and can be costly and
labor intensive. As many candidate biomarkers will not be
validated, few researchers are interested in devoting time and
money to a project that will likely not result in a publication,
as there is limited interest on the part of prominent journals
in publishing negative results. This leads to signiﬁcant
publication bias, which all of us as editors and reviewers are
in part responsible for.
As new proteomic-based biomarkers are discovered, it is
increasingly important that a mechanism exists by which the
most promising biomarkers can be validated using external
samples. This will require a collaborative eﬀort on the part
of the leading melanoma research centers. As an example
of this, the National Cancer Institute has created the Early
Detection Research, which hopes to promote biomarker
discovery, validation, and translation into clinical practice
for biomarkers associated with screening and risk [45].
Similar disease-speciﬁc collaborative eﬀorts, centered on
prospectively collecting data, blood and tumor tissue from
multiple centers not for biomarker discovery but rather
for validation, will be necessary to validate prognostic and
predictive biomarkers.
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